[Treatment of the psychological and behavioural disorders of Alzheimer's disease].
When psychological and behavioral disorders of Alzheimer's disease appear suddenly, somatic, iatrogenic and reactive or relational psychological causes must be ruled out or treated before concluding that the cause is lesional. Non-pharmacological interventions should be privileged for the prevention and management of behavioral manifestations of mild to moderate intensity: psychological support of the patient (short therapies), training the caregiver, work on daily habits, reorganization of the home, behavioral measures against apathy and especially agitation, rehabilitation strategies, and therapy involving music, light, aromas, etc. Pharmacological therapies are only moderately effective in these disorders. They must be targeted and follow a sequence of prescription that maximizes tolerance and distinguishes treatment of acute and chronic states. Anticholinesterase agents may be useful in this domain to prevent or ease some symptoms (especially apathy). The efficacy of memantine must be confirmed by additional data. Some selective serotonin reuptake inhibitors agents may be useful not only in depression but also anxiety, emotional disturbances, irritability and compulsiveness. Atypical neuroleptics are better tolerated than the classic ones. They are most effective in this context but must be reserved for specific indications and limited in time because of the increased risk of stroke. Other psychotropics (benzodiazepines, carbamates, antiepileptics) should be used cautiously in this context.
Pancrazi
M-P
MP
Hôpital Notre Dame de Bon Secours, Paris. mp.pancrazi@wanadoo.fr
Metais
P
P
D000203:Activities of Daily Living; D000544:Alzheimer Disease / Q000150:complications* / Q000188:drug therapy / Q000523:psychology / Q000534:rehabilitation / Q000628:therapy; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D006701:Home Nursing; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007326:Institutionalization; D007398:Interpersonal Relations; D001523:Mental Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D018697:Nootropic Agents / Q000627:therapeutic use; D011613:Psychotherapy; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D006993:Hypnotics and Sedatives; D018697:Nootropic Agents; D017367:Selective Serotonin Reuptake Inhibitors